GSK, osteoarthritis and Relation

Relation-GSK to drive fibrotic and osteoarthritis developments
The multi-programme partnership will also see Relation applying its platform to a range of fibrotic conditions as well as osteoarthritis. GSK will hold global development and comm
Relation and GSK join forces to advance fibrotic diseases and osteoarthritis therapies
Big pharma company GSK and UK AI-biotech Relation Therapeutics have entered into two strategic collaborations to identify and validate new therapeutic targets for osteoarthritis and fibrotic diseases.
GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets
GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for fibrotic diseases and osteoarthritis. | GSK has handed over $45 million upfront to fellow London,
GSK teams with Relation to advance fibrotic, osteoarthritis therapies
As part of the deal, GSK will pay Relation $45 million in upfront payments, which includes an equity investment of $15 million.
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
FOR IMMEDIATE RELEASERelation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and
GSK, Relation Therapeutics Partner to Advance Osteoarthritis, Fibrotic Disease Treatments
Relation Therapeutics and GSK signed two contracts to discover and develop new therapeutic targets to treat osteoarthritis and fibrotic disease.
Relation inks two GSK deals tackling osteoarthritis, fibrotic disease
Relation Therapeutics Ltd. has delivered the first commercial validation of its combined wet lab/in silico platform for homing in on disease-related genes in the thick of the genome, signing two collaboration agreements with GSK plc,
Relation Thera announces two strategic collaborations with GSK
UK-based biotech Relation Therapeutics today announced two multi-program strategic collaborations with pharma major GSK. The collaborations will focus on the identification and validation of novel therapeutic targets for fibrotic diseases and osteoarthritis.
Business Insider11h
Barclays Remains a Hold on GlaxoSmithKline (GSK)
This means that over the past quarter there has been an increase of insiders buying their shares of GSK in relation to earlier this year. TipRanks tracks over 100,000 company insiders, identifying ...
ENDPOINTS NEWS2d
'It's the bi­ol­o­gy, stu­pid': Re­la­tion and GSK team up on fi­bro­sis, os­teoarthri­tis
Machine learning and AI have sparked a transformation in drug discovery, but cracking the biology is still paramount. That's ...